Datametrex Ai Li Stock Price, News & Analysis

Datametrex AI Limited announced a non-brokered private placement financing of up to $3 million through an offering of up to 37.5 million Common Shares at $0.08 per share. The proceeds will be used to expand the company's healthcare product offering, relocate two healthcare clinics, and for general working capital. The company may pay finders' fees of up to 10% cash and 10% broker warrants. The private placement is subject to TSX Venture Exchange approval, and all issued securities will have a four-month and one-day hold period. The placement will not create a new control person, and the securities are not registered under the U.S. Securities Act.

Datametrex AI Limited (DTMXF) has completed the acquisition of Arbutus Health and Wellness Inc., a Vancouver-based multidisciplinary medical clinic. The acquisition was executed through a share exchange agreement dated June 5, 2025, where Datametrex acquired 100% of Arbutus Health's shares in exchange for 11 million common shares at $0.10 per share, valued at $1.1 million. Arbutus Health offers various healthcare services including walk-in services, family medicine, and skin laser treatments in a single location. The transaction, which requires final TSXV approval, will not result in any debt assumption, fundamental change, or change of control for Datametrex. The acquisition aligns with Datametrex's strategy to expand its healthcare sector presence.

Datametrex AI (DTMXF) has signed a non-binding Letter of Intent to acquire Arbutus Health and Wellness Inc., a Vancouver-based multidisciplinary medical clinic, for $1.1 million. The acquisition will be completed through the issuance of common shares at $0.10 per share.

Arbutus Health provides walk-in services, family medicine, skin laser treatments, and specialty healthcare services in a single location. The transaction requires customary closing conditions, definitive agreements, and regulatory approvals.

In a separate announcement, Richard Yoon has resigned from the Board of Directors effective March 28, 2025, with the company initiating a search for his replacement.

Datametrex AI (DTMXF) has announced a strategic restructuring plan focusing on healthcare and AI businesses. The company plans to expand its healthcare operations through M&A, targeting clinic acquisitions to provide family medicine, walk-in examinations, and specialist care. The expansion includes wellness services like IV therapy, Botox, and laser treatments.

As part of its 'deep and narrow' strategy, Datametrex will discontinue non-core operations in pharmacy and mobile gaming. The company reports strong cash flows from its AI service operations and aims to optimize AI solutions while exploring new partnerships.

A significant corporate restructuring is planned to split the company into two separate entities, focusing independently on healthcare and AI operations, aimed at enhancing operational efficiency and shareholder value.

Datametrex AI (TSXV:DM, FSE:D4G, OTCQB:DTMXF) has announced the effective date for its share consolidation. Starting February 19, 2025, the company's shares will trade on the TSX Venture Exchange on a consolidated basis, with a ratio of one post-consolidation share for every thirty pre-consolidation shares. The company will maintain its current name during this process. Following the consolidation, the total number of outstanding shares will be approximately 21,002,671, subject to rounding for fractional shares. The company's new ISIN number for post-consolidation shares will be CA23809L2075.

Datametrex AI (TSXV:DM, OTCQB:DTMXF) has announced a proposed share consolidation on a 30:1 basis, following shareholder approval from November 13, 2024. The consolidation will reduce the outstanding shares from 630,080,158 to approximately 21,002,671 shares.

Management states this consolidation is necessary to optimize the capital structure and attract financing. The consolidation is pending regulatory and TSX Venture Exchange approval. Fractional shares less than 1/2 will be cancelled, while those 1/2 or greater will be rounded up. The company will retain its 'DM' trading symbol, though it will receive a new ISIN number: CA23809L2075.

Registered shareholders will receive instructions via mail for exchanging their pre-consolidation shares, while no action is required from non-registered shareholders.

Datametrex AI (TSXV:DM, OTC PINK:DTMXF) announced that its wholly owned subsidiary, Datametrex Korea, has secured Purchase Orders for service and tech support valued at approximately $1.1M as of January 31, 2025. The company expects a significant gross profit margin of approximately 63% from these orders. The achievement highlights the continued growth of the company's AI and Tech division and demonstrates its strong financial performance in delivering value to clients.

Datametrex AI (TSXV:DM, OTC PINK:DTMXF) has announced that its subsidiary, Datametrex Korea, secured a new Purchase Order worth $440,000 on December 30, 2024. The order comes with a projected gross profit margin of approximately 33%.

The company states this achievement demonstrates their effectiveness in the IT industry through their land and expand strategy, highlighting the strong performance of their AI & Tech division and the strength of their client partnerships.

Datametrex AI (TSXV:DM, OTC:DTMXF) has announced the cancellation of 12,000,000 unvested restricted share units (RSUs) previously held by former employees, directors, and officers. This follows earlier grants of 22,100,000 RSUs on January 29, 2024 (vesting January 29, 2025) and 12,500,000 RSUs on February 15, 2024 (vesting February 15, 2025). After these cancellations, 22,600,000 RSUs remain outstanding under the company's 2023 omnibus incentive plan. The company states it remains committed to aligning its incentive plans with operational goals.